Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM
- Conditions
- Gestational Diabetes
- Registration Number
- NCT05392231
- Lead Sponsor
- Haseki Training and Research Hospital
- Brief Summary
The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).
- Detailed Description
The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).In this prospective observational study including 109 pregnant women, the fetal pancreas size and maternal serum biomarkers GA and IRAP were measured at the gestational age of 20-22 weeks and later at the gestational age of 24-28 weeks, in 19 participants of them, GDM was confirmed with the 75-g oral glucose tolerance test (OGTT) and the fetal pancreas size was measured in all the participants again.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 109
- Maternal age between 18 and 42 years
- Gestational age between 20 and 28 weeks
- Multiple pregnancies
- Pregestational diabetes
- Fetal congenital malformations
- Placental and amniotic fluid abnormalities
- Preeclampsia
- Severe systemic disease
- Long-term systemic drug usage
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Early prediction of gestational diabetes Two months Early prediction of gestational diabetes by the fetal pancreas measurement with ultrasound and maternal serum biomarkers glycated albumin and insulin-regulated aminopeptidase measured with ELISA
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Haseki Training and Research Hospital
🇹🇷İstanbul, Turkey